Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 32%
Hold 26%
Sell 0%
Strong Sell 5%

Bulls say

Arvinas Inc. is well-positioned for a positive financial outlook due to its innovative approach in developing therapies that utilize the PROTAC platform, which demonstrated notable enhancements in safety profiles and potency in comparative assays. The advantages shown by ARV-806, particularly its superior efficacy in reducing KRAS G12D protein and enhancing immune response compared to existing inhibitors, indicate significant potential for its application in cancer treatment. With upcoming milestones, including the anticipated approval of vepdeg by June 2025, the company's strategic focus on improving treatment outcomes for challenging diseases reinforces confidence in its future growth prospects.

Bears say

Arvinas Inc. faces a negative outlook primarily due to significant revenue forecasts being downgraded, with peak vepdeg revenue expectations slashed to $296.9 million from a prior estimate of $641.2 million, indicating challenges in market penetration and partnered economics. Furthermore, the company’s inability to access capital could hinder critical business functions, potentially delaying profitability and sustainable cash flow generation. Additionally, a sequential decline in expenditures on key product candidates reflects a reduced commitment to development spending, which may impede the company's ability to defend its market position and hinder growth prospects.

Arvinas Inc (ARVN) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 32% recommend Buy, 26% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 19 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.